Remdesivir, HCQ don't aid much in recovery of Covid-19 patients: WHO trials

While Gilead calls for review, the findings can have significant impact on the growing demand of remdesivir

Gilead’s remdesivir has little or no impact on Covid-19 patients' length of hospital stay, initiation of ventilation, or chances of survival, a clinical trial by the World Health Organization (WHO) has found. 

The US biotech giant, however, questioned the findings of the study, saying these were premature and the data appeared inconsistent. Other studies, the firm said, had validated the drug's benefits.

Listed pharmaceutical companies that manufacture remdesivir in India -- Cadila Healthcare, Cipla, and Jubilant Life Sciences -- seemed to defy the negative news, as their shares ended the day in the green. Cadila Healthcare’s stock was, in fact,